Acuitas: noun, insight, perception, sharpness.

Michael J. Hope Ph.D., Consultant

Michael-Hope-headshotDr. Hope obtained his BSc. and Ph.D. in Biochemistry from the University of London, U.K. He has held senior academic and industry positions including Assistant Professor in the Department of Medicine, University of British Columbia, Vice-President Research at the Canadian Liposome Company and Principal Scientist at Tekmira Pharmaceuticals before joining Acuitas. Dr. Hope has extensive experience in all aspect of liposome research including biophysical characterization and preclinical testing and development. This includes leading research teams responsible for the conduct of preclinical pharmacodynamic, pharmacokinetic and safety studies to support several Investigational New Drug (IND) applications for liposomal therapeutic products including Marqibo™, Alocrest™ and Brakiva™. Dr. Hope is an author on over 100 publications in peer-reviewed journals.

Our History

Acuitas Therapeutics is a private company incorporated in British Columbia, Canada. We were founded in February 2009 (initially as AlCana Technologies) and have partnered with Alnylam Pharmaceuticals, the University of British Columbia, IRAP and others on several research and development programs relating to systemic delivery of nucleic acid therapeutics.
Contact Information

Twitter Feed

Find out what's happening, right now, with Acuitas Therapeutics.

Copyright 2018 Acuitas Therapeutics. Web Design by Tommy Le Inc.